

RNS Number : 9527D  
EKF Diagnostics Holdings PLC  
23 May 2012

23 May 2012

**EKF Diagnostics Holdings plc  
("EKF" or "the Company")**

**Result of Annual General Meeting**

EKF Diagnostics Holdings plc (AIM: EKF), growing in-vitro diagnostics company, announces that at its Annual General Meeting, held today at 11:00am at the offices of Canaccord Genuity Limited, 88 Wood Street, London EC2V 7QR, all resolutions, the voting of which was conducted by way of a poll, were duly passed.

**Enquiries:**

**EKF Diagnostics Holdings plc**                      **Tel: 029 2071 0570**

David Evans, Executive Chairman      Mob: 07740 084 452  
Julian Baines, CEO                      Mob: 07788 420 859

**Canaccord Genuity Limited**              **Tel: 020 7523 8000**

Jamie Adams / Mark Dickenson / Lucy Tilley

**Walbrook PR Limited**                      **Tel: 020 7933 8780**

Paul McManus                              Mob: 07980 541 893 or  
[paul.mcmanus@walbrookpr.com](mailto:paul.mcmanus@walbrookpr.com)  
Fiona Henson                              Mob: 07886 335 992 or [fiona.henson@walbrookpr.com](mailto:fiona.henson@walbrookpr.com)

**About EKF Diagnostics Holdings plc**

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US\$25.5m).

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"),

a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo\_Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

For more information please visit the website: [www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)

This information is provided by RNS  
The company news service from the London Stock Exchange

END

RAGSEFFDFESEII admin Result of AGM 20117357 A Wed, 05/23/2012 - 13:00 Results and Trading Reports EKF